Mioritmil is prescribed: with tachyarrhythmia associated with WPW syndrome; with blinking, atrial flutter; with tachyarrhythmias of a paroxysmal nature (including ventricular fibrillation, atrioventricular, atrial, ventricular tachycardia), when other drugs cannot be prescribed.
active substance: amiodarone;
1 tablet contains 200 mg of amiodarone hydrochloride;
excipients: lactose monohydrate, potato starch, povidone, microcrystalline cellulose, crospovidone, magnesium stearate.
Mioritmil is a class III antiarrhythmic agent used for cardiac arrhythmias. It also has alpha / beta-adrenergic blocking, antianginal, coronary dilating, hypotensive effects.
Mioritmil is prescribed:
- with tachyarrhythmia associated with WPW syndrome;
- with blinking, atrial flutter;
- with tachyarrhythmias of a paroxysmal nature (including ventricular fibrillation, atrioventricular, atrial, ventricular tachycardia), when other drugs cannot be prescribed.
Do not prescribe Mioritmil:
- with iodine allergy;
- with intolerance to the components of the drug;
- with sick sinus syndrome;
- with atrioventricular block II – III century. (without the use of a pacemaker);
- with sinus bradycardia;
- with sinoatrial blockade;
- with arterial hypotension;
- with hypothyroidism;
- with thyrotoxicosis;
- with cardiogenic shock;
- with hypokalemia;
- with collapse;
- with interstitial lung diseases;
- with congenital / acquired lengthening of the Q – T interval;
- when taking monoamine oxidase inhibitors;
- with two-, three-beam blockages;
- with hypomagnesemia;
- with hypothyroidism / hyperthyroidism;
- while taking medications that lengthen the Q – T interval;
- during pregnancy / lactation.
It is used with caution in chronic heart failure (III-IV FC), AV blockade of the I degree, bronchial asthma, liver failure, in old age.
The safety and efficacy of using amiodarone in children has not been evaluated at this time, therefore, the appointment of this drug for children is not recommended.
Application during pregnancy and lactation
Method of administration and dosage
The tablet is taken orally with water, during or after meals.
The initial dose is 600-800 mg / day (in several doses), the maximum is 1200 mg / day until the total dose is 10,000 mg (within 5-8 days).
The maintenance dose is 100–400 mg / day.
Overdose symptoms: paroxysmal tachycardia “pirouette”, drop in blood pressure, bradycardia, cardiac arrest, atrioventricular block, impaired renal / liver function.
Treatment: gastric lavage, the appointment of sorbents, cholestyramine, with bradycardia – beta-adrenostimulants, with tachycardia “pirouette” – magnesium salts, cardiac stimulation.
- Neurological disorders: myopathy, pseudotumor of the brain, peripheral neuropathy, headache, sleep disturbances, extrapyramidal symptoms, cerebellar ataxia.
- Digestive disorders: decreased appetite, dullness / loss of taste, nausea, heaviness in the stomach, development of liver failure, pseudo-alcoholic hepatitis, toxic hepatitis, cirrhosis.
- Cardiovascular disorders: SA / AV block, sinus node arrest, moderate bradycardia, proarrhythmogenic effect, severe bradycardia, progression of heart failure.
- Respiratory disorders: bronchospasm, pleurisy, pulmonary fibrosis, interstitial / alveolar pneumonitis, bronchiolitis obliterans with pneumonia, pulmonary hemorrhage.
- Perceptual disorders: microdeposits in the epithelium of the cornea, optic neuritis, visual neuropathy.
- Skin changes: rash, grayish / bluish skin pigmentation, alopecia, photosensitivity, exfoliative dermatitis.
- Metabolic disorders: hyperthyroidism / hypothyroidism, disorder of ADH secretion.
- Others: aplastic, epididymitis, impotence, vasculitis, thrombocytopenia, hemolytic anemia.
Storage conditions and periods
Store no more than 2 years at 15-25 ° C.